Glucosamine sulfate in osteoarthritis of the knee

https://doi.org/10.1016/S1063-4584(05)80006-8Get rights and content

Summary

Glucosamine sulfate is a drug used for the treatment of osteoarthritis (OA), based on its pharmacological and metabolic activities on the cartilage and chondrocytes, complemented by mild anti-inflammatory properties and a favorable pharmacokinetic profile.

The aim of this study was to define the activity and safety of glucosamine sulfate on the symptoms of patients with OA, using a multicenter, randomized, placebo-controlled, double-blind, parallel-group study design. The study included 252 outpatients with OA of the knee (Lequesne's criteria), radiological stage between I and III, and Lequesne's severity index of at least 4 points and symptoms for at least 6 months. Patients were treated with either placebo or oral glucosamine sulfate 500 mg t.i.d. for 4 weeks, with weekly clinic visits. Responders to treatment were defined as patients with a reduction of at least 3 points in the Lequesne's index with a positive overall assessment by the investigator.

The Lequesne's index was 10.6±0.45 s.e.m. points in both groups at the start of the study. This decreased to 7.45±0.5 points in the treatment group (average 3.2) and 8.4±0.4 points in the placebo group (average 2.2) (P < 0.05, Student's t-test). The responder rate in the evaluable patients was 55% with glucosamine (N = 120) vs 38% with placebo (N = 121). These proportions were 52% vs 37% in an intention-to-treat analysis (P = 0.014 and 0.016, respectively; Fisher's Exact Test). The medications were well tolerated throughout the study, with no difference between the glucosamine and placebo treated groups.

It is concluded that glucosamine sulfate may be a safe and effective symptomatic Slow Acting Drug for OA.

References (60)

  • RodenL

    Effect of hexosamines on the synthesis of chondroitin sulphuric acid in vitro

    Arkh Kemi

    (1956)
  • KarzelK et al.

    Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycan metabolism of fibroblast cultures

    Pharmacology

    (1971)
  • Vidal y PlanaRR et al.

    Glucosamine: its role in the articular cartilage metabolism 2. Studies on rat and human articular cartilage

    Fortschr Med

    (1980)
  • BassleerC et al.

    In-vitro evaluation of drugs proposed as chondroprotective agents

    Int J Tissue React

    (1992)
  • SetnikarI et al.

    Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C]-glucosamine to the rat

    Pharmatherapeutica

    (1984)
  • SetnikarI et al.

    Pharmacokinetics of glucosamine in the dog and in man

    Arzneimittelforschung

    (1986)
  • EichlerJ et al.

    Therapy of deforming arthrosis through the action upon the cartilagineous metabolism

    Orthop Prax

    (1970)
  • CrolleG et al.

    Glucosamine sulfate for the management of arthrosis: a controlled clinical investigation

    Curr Med Res Opin

    (1980)
  • DrovantiA et al.

    Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo controlled double-blind investigation

    Clin Ther

    (1980)
  • Mund-HoymWD

    Medical treatment of spinal arthrosis with glucosamine or phenylbutazone. A controlled study

    Therapiewoche

    (1980)
  • PujalteJM et al.

    Double-blind clinical evaluation of oral glucosamine sulfate in the basic treatment of osteoarthrosis

    Curr Med Res Opin

    (1980)
  • D'AmbrosioE et al.

    Glucosamine sulfate: a controlled clinical investigation in arthrosis

    Pharmatherapeutica

    (1981)
  • Lopez VazA

    Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulfate in the management of osteoarthrosis of the knee in out-patients

    Curr Med Res Opin

    (1982)
  • LequesneMG

    Clinical features, diagnostic criteria, functional assessment and radiological classifications of osteoarthritis

    Rheumatol Int

    (1982)
  • WeselohG et al.

    Therapeutic aspects in degenerative joint destruction

    Orthopade

    (1983)
  • KellgrenJH et al.

    Radiological assessment of osteoarthritis

    Ann Rheum Dis

    (1957)
  • LequesneMG et al.

    Indexes of severity for osteoarthritis of the hip and knee. Validation-Value in comparison with other assessment tests

    Scand J Rheumatol

    (1987)
  • SanderA

    Principles for the proper conduct of clinical drug trials (translated from Bundesanzeiger 243, 1987, p. 16617)

    Drugs made in Germany

    (1989)
  • PocockSJ

    Protocol deviations

  • Cited by (190)

    • Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis

      2014, Carbohydrate Polymers
      Citation Excerpt :

      The metabolic fate of partially depolymerized chondroitin-S is similar in man and laboratory animals. The subject of GlcN.S as a nutraceutical has been reviewed by Aghazadeh-Habashi and Jamali (2011), Anderson, Nicolosi, and Borzelleca (2005), Deal and Moskowitz (1999), Herrero-Beaumont and Rovati (2006), Ibrahim, Gilzad-Kohan, Aghazadeh-Habashi, and Jamali (2012), Kean and Thanou (2010), Laverty, Sandy, Celeste, Vachon, Marier, and Plaas (2005), Matheson and Perry (2003), Muzzarelli and Muzzarelli (2006), Noak et al. (1994), Tamai et al. (2002), Towheed (2003), and Welch et al. (2012), among others. GlcN (2-amino-2-deoxy-β-d-glucopyranose) is an endogenous aminomonosaccharide biosynthesized from glucose, as already noted in Scheme 1 (Leffler, Philippi, Leffler, Mosure, & Kim, 1999; Runkel & Cupp, 1999).

    • Pharmacotherapy of joint and tendon disease

      2013, Equine Sports Medicine and Surgery: Second Edition
    View all citing articles on Scopus
    View full text